Ongoing aortic wall degeneration and subsequent aneurysm exclusion failure are major\nconcerns after an endovascular aneurysm repair with a stent-graft. An ideal solution would be a drug\ntherapy that targets the aortic wall and inhibits wall degeneration. Here, we described a novel drug\ndelivery system, which allowed repetitively charging a graft with therapeutic drugs and releasing\nthem to the aortic wall in vivo. The system was composed of a targeted graft, which was labeled with\na small target molecule, and the target-recognizing nanocarrier, which contained suitable drugs. We\ndeveloped the targeted graft by decorating a biotinylated polyester graft with neutravidin. We created\nthe target-recognizing nanocarrier by conjugating drug-containing liposomes with biotinylated\nbio-nanocapsules. We successfully demonstrated that the target-recognizing nanocarriers could bind\nto the targeted graft, both in vitro and in blood vessels of live mice. Moreover, the drug released\nfrom our drug delivery system reduced the expression of matrix metalloproteinase-9 in mouse aortas.\nThus, this hybrid system represents a first step toward an adjuvant therapy that might improve the\nlong-term outcome of endovascular aneurysm repair.
Loading....